Overview

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Status:
Recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.

Phase:

Phase 3

Details

Lead Sponsor:

GCS IHFB Cognacq-Jay

Collaborator:

Fondation ARCAD

Treatments:

Aflibercept